A summary of monoclonal antibody-enzyme/prodrug

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 341-349

  Senter, Peter D ^a   Svensson, Håkan P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

anticancer prodrugs; antitumor activities; monoclonal antibodies; pharmacokinetic data

Indexed keywords

ANTIBODIES; CELLS; DISEASES; DRUG THERAPY; ENZYMES; MONOCLONAL ANTIBODIES; OXYGEN; PHARMACOKINETICS;

ANTIBODY ENZYME CONJUGATES; ANTICANCER PRODRUGS; ANTITUMOR ACTIVITY;

DRUG PRODUCTS;

ALKALINE PHOSPHATASE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ARYLSULFATASE; BETA GALACTOSIDASE; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BETA LACTAMASE; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE G2; CYTOSINE DEAMINASE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ENZYME; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; METHOTREXATE; MITOMYCIN; MONOCLONAL ANTIBODY; NITROREDUCTASE; OXYGEN RADICAL; PACLITAXEL; PALYTOXIN; PENICILLIN AMIDASE; PRODRUG; UNINDEXED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL SURFACE; DRUG MECHANISM; DRUG TARGETING; HUMAN; MEDICAL RESEARCH; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0030589728     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00445-0     Document Type: Review

References (57)

1. [1] Wilman, D.E.V. (1986) Prodrugs in cancer chemotherapy. Biochem. Soc. Trans. 14, 375-382.
2. [2] Denny, W.A. (1988) New directions in the design and evaluation of anti-cancer drugs. Drug Des. Deliv. 3, 99-124.
3. [3] Conners, T.A. (1986) Prodrugs in cancer chemotherapy. Xenobiotica 16, 975-988.
4. [4] Senter, P.D., Wallace, P.M., Svensson, H.P., Vrudhula, V.M., Kerr, D.E., Hellström, I. and Hellström, K.E. (1993) Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem. 4, 3-9.
5. [5] Jungheim, L.N. and Shepherd, T.A. (1994) Design of anticancer prodrugs: substrates for antibody targeted enzymes. Chem. Rev. 94, 1553-1566.
6. [6] Philpott, G.W., Shearer, W.T., Bower, R.W. and Parker C.W. (1973) Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate. J. Immunol. 111, 921-929.
7. [7] Ito, H., Morizet, J., Coulombel, L., Goavec, M., Rousseau, V., Bernard, A. and Stanislawski, M. (1989) An immunotoxin system intended for bone marrow purging composed of glucose oxidase and lactoperoxidase coupled to monoclonal antibody 097. Bone Marrow Transplant. 4, 519-527.
8. [8] Ito, H., Morizet, J., Coulombel, L. and Stanislawski, M. (1990) T cell depletion of human bone marrow using an oxidase-peroxidase enzyme immunotoxin. Bone Marrow Transplant. 6, 395-398.
9. [9] Battelli, M G., Abbondanza, A., Tazzari, P.L., Donota, A., Rizzi, S., Grassi, M. and Stirpe, F. (1988) Selective cytotoxicity of an oxygen-radical-generating enzyme conjugated to a monoclonal antibody. Clin. Exp. Immunol. 73, 128-133.
10. [10] Dinota, A., Tazzari, P.L., Abbondanza, A., Battelli, M.G., Gobbi, M. and Stirpe, F. (1990) Bone marrow purging by a xanthine oxidase-antibody conjugate. Bone Marrow Transplant. 6, 31-36.
11. [11] Yoshikawa, T., Kokura, S., Tainaka, K., Naito, Y. and Kondo, M. (1995) A novel cancer therapy based on oxygen radicals. Cancer Res. 55, 1617-1620.
12. [12] Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.L., Brown, J.P., Hellström, I. and Hellström, K.E. (1988) Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842-4846.
13. [13] Senter, P.D., Su, P.C.D., Katsuragi, T., Sakai, T., Cosand, W.L., Hellström, I. and Hellström, K.E. (1991) Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem. 2, 447-451.
14. [14] Svensson, H.P., Vrudhula, V.M., Emsweiler, J.E., MacMaster, J.F., Cosand, W.L., Senter, P.D. and Wallace, P.M. (1995) In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Cancer Res. 55, 2357-2365.
15. [15] Deonarain, M.P. and Epenetos, A.A. (1994) Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer 70, 786-794.
16. [16] Knox, R.J. and Conners, T.A. (1995) Antibody-directed enzyme prodrug therapy. Clin. Immunother. 3, 136-153.
17. [17] Meyer, D.L., Jungheim, L.N., Law, K.L., Mikolajczyk, S.D., Shepherd, T.A., Mackensen, D.G., Briggs, S.L. and Starling, J.J. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956-3963.
18. [18] Kerr, D.E., Schreiber, G.L., Vrudhula, V.M., Svensson, H.P., Hellström, I., Hellström, K.E. and Senter, P.D. (1995) Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 55, 3558-3563.
19. [19] Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D. and Wallace, P.M. (1993) Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem. 4, 334-340.
20. [20] Antoniw, P., Springer, C.J., Bagshawe, K.D., Searle, F., Melton, R.G., Rogers, G.T., Burke, P.J. and Sherwood, R.F. (1990) Disposition of the prodrug 4-(bis(2-chloroethyl)amino)benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer 62, 909-914.
21. [21] Wallace, P.M., MacMaster, J.F., Smith, V.F., Kerr, D.E., Senter, P.D. and Cosand, W.L. (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 54, 2719-2723.
22. [22] Bosslet, K., Czech, J. and Hoffmann, D. (1994) Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54, 2151-2159.
23. [23] Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellström, K.E. and Hellström, I. (1989) Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin c and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49, 5789-5792.
24. [24] Haisma, H.J., Boven, E., van Muijen, M., De Vries, R. and Pinedo, H.M. (1992) Analysis of a conjugate between anti-carcinoembrionic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother. 34, 343-348.
25. [25] Sahin, U., Hartmann, F., Senter, P., Pohl, C. Engert, A., Diehl, V. and Pfreundschuh, M. (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/ anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50, 6944-6948.
26. [26] Senter, P.D. (1990) Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4, 188-193.
27. [27] Wallace, P.M. and Senter, P.D. (1991) In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2, 349-352.
28. [28] Roffler, S.R., Wang, S.-M., Chern, J.-W., Yeh, M.-Y. and Tung, E. (1991) Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. 42, 2062-2065.
29. [29] Roffler, S.R., Chern, J.-W., Yeh, M.-Y., Ng, J.C. and Tung, E. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res. 52, 4484-4491.
30. [30] Haisma, H.J., Boven, E., van Muijen, M., de Jong, J., van der Vijgh, W.J.F. and Pinedo, H.M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474-478.
31. [31] Haenseler, E., Esswein, A., Vitols, K.S., Montejano, Y., Mueller, B.M., Reisfeld, R.A. and Huennekens, F.M. (1992) Activation of methotrexate-α-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 31, 891-897.
32. [32] Kuefner, U., Lohrmann, U., Montejano, Y.D., Vitols, K.S. and Huennekens, P.M. (1989) Carboxypeptidase-mediated release of methotrexate from methotrexate-α-peptides. Biochemistry 28, 2288-2297.
33. [33] Esswein, A., Hansler, E., Montejano, Y, Vitols, K.S. and Huennekens, F.M. (1991) Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate. Adv. Enzyme Regul. 31, 3-12.
34. [34] Vitols, K.S., Haag-Zeino, B., Baer, T., Montejano, Y.D. and Huennekens, F.M. (1995) Methotrexate-α-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res. 55, 478-481.
35. [35] Bagshawe, K.D., Springer, C.J., Searle, F., Antiniw, P., Sharman, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
36. [36] Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, P., Bisset, G.M.F. and Jarman, M. (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33, 677-681.
37. [37] Springer, C.J., Bagshawe, K.D., Sharma, S.K., Searle, F., Boden, J.A., Antoniw, P., Burke, P.J., Rogers, G.T., Sherwood, R.F. and Melton, R.G. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366.
38. [38] Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, R.W. and Rogers, G.T. (1990) Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br. J. Cancer 61, 659-662.
39. [39] Sharma, S.K., Bagshawe, K.D., Springer, C.J., Burke, P.J., Rogers, G.T., Boden, J.A., Antoniw, P., Melton, R.G. and Sherwood, R.F. (1991) Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis. Markers 9, 225-231.
40. [40] Eccles, S.A., Court, W.J., Box, G.A., Dean, C.J., Melton, R.G. and Springer, C.J. (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res. 54, 5171-5177.
41. [41] Rowlinson-Busza, G., Bamias, A., Krausz, T. and Epenetos, A.A. (1992) Antibody-guided enzyme nitrile therapy (Agent): in vitro cytotoxicity and in vivo tumour localisation. In: A.A. Epenetos (Ed.), Monoclonal Antibodies 2. Applications in Clinical Oncology. Chapman and Hall, London, pp. 111-118.
42. [42] Gesson, J.-P., Jacquesy, J.-C., Mondon, M., Petit, P., Renoux, B., Andrianomenjanahary, S., Dufat-Trinh Van, H., Koch, M., Michel, S., Tillequin, F., Florent, J.-C., Monneret, C., Bosslet, K., Czech, J. and Hoffman, D. (1994) Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anticancer Drug Design 9, 409-423.
43. [43] Kerr, D.E., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellström, I. and Hellström, K.E. (1990) Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31, 202-206.
44. [44] Vrudhula,V.M., Senter, P.D., Fischer, K.J. and Wallace, P.M. (1993) Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J. Med. Chem. 36, 919-923.
45. [45] Bignami, G.S., Senter, P.D., Grothaus, P.G., Fischer, K.J., Humphreys, T. and Wallace, P.M. (1992) N-(4′-Hydroxyphenyl)palytoxin: A palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. 52, 5759-5764.
46. [46] Mauger, A.B., Burke, P.J., Somani, H.H., Friedlos, F. and Knox, R.J. (1994) Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37, 3452-3458.
47. [47] Shepherd, T.A., Jungheim, L.N., Meyer, D.L. and Starling. J.J. (1991) A novel targeted delivery system utilizing a cephalosporin oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg. Med. Chem. Lett. 1, 21-26.
48. [48] Meyer, D.L., Jungheim, L.N., Mikolajczyk, S.D., Shepherd, T.A., Starling, J.J. and Ahlem, C. (1992) Preparation and characterization of β-lactamase-Fab' conjugates for the site specific activation of oncolytic agents. Bioconjugate Chem. 3, 42-48.
49. [49] Jungheim, L.N., Shepherd, T.A. and Meyer, D.L. (1992) Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: substrates for an antibody-targeted enzyme. J. Org. Chem. 57, 2334-2340.
50. [50] Alexander, R.P., Beeley, N.R.A., O'Driscoll, M., O'Neill, P.P., Millican, T.A., Pratt, A.J. and Willenbrock, F.W. (1991) Cephalosporin nitrogen mustard carbamate prodrugs for 'ADEPT'. Tetrahedron Lett. 32, 3269-3272.
51. [51] Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M. and Senter, P.D. (1992) Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem. 3. 176-181.
52. [52] Vrudhula, V.M., Svensson, H.P. and Senter, P.D, (1995) Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody β-lactamase conjugates. J. Med. Chem. 38, 1380-1385.
53. HER2Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
54. [54] Senter, P.D., Svensson, H.P., Schreiber, G.J., Rodriguez, J.L. and Vrudhula, V.M. (1995) Polyethylene glycol)-doxorubicin conjugates containing β-lactamase-sensitive linkers. Bioconjugate Chem. 6, 389-394.
55. [55] Hanessian, S. and Wang, J. (1993) Design and synthesis of cephalosporin-carboplatinum prodrug activatable by a β-lactamase. Can. J. Chem. 71, 896-906.
56. [56] Rodrigues, M.L., Carter, P., Wirth, C., Mullins, S., Lee, A. and Blackburn, B.K. (1995) Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol. 2, 223-227.
57. [57] Senter, P.D., Vrudhula, V.M., Wallace, P.M., Sommerville, J.E., Wang, I.-K. and Lowe, D.A. (1995) Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfatase. Drug Deliv. 2, 110-116.